Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Advanced Course on Role of CDK4/6 Inhibitors in Hormone Receptor Positive HER2 Negative in Breast Cancer 2024: Jeddah

07 - 07 Sep 2024

Jeddah, Saudi Arabia

ESMO-Advanced-Courses-Breast-Cancer-1000x1000

Slides and Webcasts from all ESMO Advanced Courses are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.

The copyright protected educational resources from this event are for personal usage only and not to be shared with any third parties.

Learning objectives
  • Understanding the function and biology of CDK4-6 in breast cancer
  • Information and in-depth discussion on the state of the art and emerging therapeutic strategies integrating CDK4-6 inhibition in breast cancer, both in the early and metastatic setting
  • Assessing the clinical and genomic features for risk of relapse in early HR+/HER2 negative breast cancer
  • Presenting novel data on biomarkers of benefit, mechanisms of resistance and combinatorial therapeutic strategies of CDK4-6 inhibition
  • Discussing clinical cancer cases to integrate use of CDK4-6 inhibitors in clinical practice

This event has been supported by an unrestricted educational grant from Novartis.

Hide
Filter by:

There are 8 resources available

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.